Affiliated with a Castle Connolly Top Hospital
Who is Dr. Neal, Medical Oncologist in Stanford, CA?
Dr. Joel Neal, MD, PHD is a Medical Oncologist, who primarily practices in Stanford, CA with 2 additional practice locations. He is board certified by the American Board of Internal Medicine. Dr. Neal graduated from Feinberg School of Medicine - Northwestern University and completed his residency at Beth Israel Deaconess Medical Center. Dr. Neal is fluent in English, and is currently seeing new patients. Dr. Neal’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Neal’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Neal?
Dr. Joel Neal, MD, PHD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Neal empowers patients to confidently navigate their health journey, specializing in Lung Cancer, Mesothelioma, Thoracic Cancers, Thymoma and Thymic Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Neal is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Neal go to medical school and complete their residency?
Fellowship: Dana-Farber Cancer Institute MA | Dana Farber Cancer Institute
Residency: Beth Israel Deaconess Medical Center
Medical School: Feinberg School of Medicine - Northwestern University
Is Dr. Neal board certified in Medical Oncologist?
Yes, Dr. Joel Neal, MD, PHD is board certified by the American Board of Internal Medicine since 2010, American Board of Internal Medicine since 2007
What languages does Dr. Neal speak?
Dr. Neal and their clinical team can communicate with patients in the following languages:
English
What conditions does Dr. Neal treat?
As a Medical Oncologist, Dr. Neal diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Neal. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Lung Cancer
- Right upper lobe lung cancer
- Bronchial cancer
- Malignant neoplasm of lung
- Pulmonary cancer
- Right lung cancer
- Left Lung Cancer
- Upper Lobe Lung Cancer
- Bronchial Cancer
- Malignant Lung Tumor
- Left lower lobe lung cancer
- Right lower lobe lung cancer
- Middle Lobe Lung Cancer
ICD-10 Codes:
- C3411: Malignant neoplasm of upper lobe, right bronchus or lung
- C3490: Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C3491: Malignant neoplasm of unspecified part of right bronchus or lung
- C3412: Malignant neoplasm of upper lobe, left bronchus or lung
- C3492: Malignant neoplasm of unspecified part of left bronchus or lung
- C3432: Malignant neoplasm of lower lobe, left bronchus or lung
- C3431: Malignant neoplasm of lower lobe, right bronchus or lung
- C342: Malignant neoplasm of middle lobe, bronchus or lung
Also known as:
- Mesothelioma
- Peritoneal Mesothelioma
- Malignant Mesothelioma Treatment (PDQ®)
- Malignant Mesothelioma Treatment (PDQ)
- Malignant Mesothelioma
- Asbestos Cancer
- Pleural Mesothelioma
- Abdominal Mesothelioma
- Malignant Peritoneal Mesothelioma
- Mesothelioma of Abdomen
- Peritoneal Asbestos Cancer
ICD-10 Codes:
- C450: Mesothelioma of pleura
- C451: Mesothelioma of peritoneum
- C459: Mesothelioma, unspecified
- C457: Mesothelioma of other sites
Also known as:
- Secondary Bone Cancer
- Secondary Brain Cancer
- Primary Cancer (Unspecified Site)
- Bone Cancer
- Brain Tumor
- Cancer
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
- Metastatic brain cancer
- Brain metastases
- Cancer spread to brain
- Malignant tumor
- Neoplasm
- Cancer of unknown primary
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
- C7931: Secondary malignant neoplasm of brain
- C801: Malignant (primary) neoplasm, unspecified
Also known as:
- Tracheal Cancer
- Head and Neck Cancer
- Tracheal Disorder
- Windpipe Cancer
- Malignant Tracheal Tumor
- Tracheal Carcinoma
ICD-10 Codes:
- C33: Malignant neoplasm of trachea
Also known as:
- Cancer Chemotherapy
- Cancer Immunotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
- Oncology immunotherapy
- Immune therapy for cancer
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
- Z5112: Encounter for antineoplastic immunotherapy
Also known as:
- Thymus Cancer
- Thymoma and Thymic Carcinoma Treatment (PDQ®)
- Thymoma
- Thymic Carcinoma
- Malignant Thymus Tumor
ICD-10 Codes:
- C37: Malignant neoplasm of thymus
Also known as:
- Skin Rash
- Rashes
- Skin Eruption
- Hives
- Dermatitis
- Skin Inflammation
ICD-10 Codes:
- R21: Rash and other nonspecific skin eruption
Which procedures does Dr. Neal perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Joel Neal may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Neal's office.
Does Dr. Neal accept my insurance?
Dr. Neal accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Neal accept in Stanford, CA?
Dr. Neal in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Central California Alliance for Health
CVS Health (formerly Aetna)
Express Scripts
Kaiser Permanente
Medicaid
Medicare
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Neal's office located?
Recognitions
Publications
A Patient With Aplastic Lymphoma Kise-Positive Non
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
JOURL OF THORACIC ONCOLOGY, 2013
Targeting fibroblast growth factor receptor
Jourl of thoracic oncology, 2012
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
JOURL OF THORACIC ONCOLOGY, 2012
Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
JOURL OF CLINICAL ONCOLOGY, 2012
Ipilimumab in Combition With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB
JOURL OF CLINICAL ONCOLOGY, 2012
Current Magement of Small Cell Lung Cancer
CLINICS IN CHEST MEDICINE, 2011
Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
JOURL OF THORACIC ONCOLOGY, 2011
The SATURN trial: the value of maintence erlotinib in patients with non-small-cell lung cancer
FUTURE ONCOLOGY, 2010
Cetuximab monotherapy in patients with advanced non
Jourl of thoracic oncology, 2010
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
ture reviews. Clinical oncology, 2010
First-line use of EGFR tyrosine kise inhibitors in patients with NSCLC containing EGFR mutations.
Clinical advances in hematology & oncology : H&O, 2010
Induction of FucT-VII by the Ras/MAP kise cascade in Jurkat T cells
BLOOD, 2003
A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts
JOURL OF BIOLOGICAL CHEMISTRY, 2003
Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells
JOURL OF BIOLOGICAL CHEMISTRY, 2002
Glycogen synthase kise-3 inhibits the D binding activity of NFATc
JOURL OF BIOLOGICAL CHEMISTRY, 2001
REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE
JOURL OF BACTERIOLOGY, 1994
A Case Series of Lengthy Progression-Free Survival With Pemetrexed
Clinical lung cancer, 2013
A Patient With Anaplastic Lymphoma Kinase-Positive Non
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
JOURNAL OF THORACIC ONCOLOGY, 2013
Aflibercept in lung cancer
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013
Targeting fibroblast growth factor receptor
Journal of thoracic oncology, 2012
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY, 2012
Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
JOURNAL OF CLINICAL ONCOLOGY, 2012
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB
JOURNAL OF CLINICAL ONCOLOGY, 2012
First-line treatment of EGFR-mutant non-small-cell lung cancer
Biologics : targets & therapy, 2012
Current Management of Small Cell Lung Cancer
CLINICS IN CHEST MEDICINE, 2011
Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY, 2011
One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer
CLINICAL CANCER RESEARCH, 2011
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
FUTURE ONCOLOGY, 2010
Cetuximab monotherapy in patients with advanced non
Journal of thoracic oncology, 2010
AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010
Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2010
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Nature reviews. Clinical oncology, 2010
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Clinical advances in hematology & oncology : H&O, 2010
Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
BLOOD, 2003
A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003
Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002
Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001
REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE
JOURNAL OF BACTERIOLOGY, 1994
What is Dr. Neal's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Neal's National Provider Identifier (NPI) number is 1790858942.
What common questions do patients ask about Dr. Neal?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Neal
What is Dr. Joel Neal's specialty?
Dr. Neal is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Neal to book an appointment today.
Is this Dr. Joel Neal affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Neal is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Joel Neal accepting new patients in Stanford, CA?
Yes, Dr. Joel Neal is accepting new patients at this time.
Does Dr. Joel Neal offer online booking?
Please contact Dr. Neal's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Joel Neal?
Please contact Dr. Neal's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Joel Neal have?
Dr. Joel Neal is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients